Antimicrobials
Voriconazole

Voriconazole

Low
Excellent

Spectrum of Activity

Dosing

General Information

HEALTH CANADA APPROVED

  • Invasive aspergillosis, candidemia in non-neutropenic patients and invasive candidiasis
  • CYP450 interactions ++
  • Other QTc prolonging agents
  • Recommend review of concomitant medications due to high frequency of significant interactions

REQUIRED

  • Observe for signs of anaphylactoid reaction (ie, chest tightness, dyspnea, faintness, flushing, nausea, sweating) for 10 minutes after the start of each dose

RECOMMENDED

  • Therapeutic drug monitoring strongly recommended to ensure adequate concentrations and exclude toxicity (Discuss with ID)

    • Target 1 – 5.5 μg/mL, 5-7 days after starting therapy
  • QTc interval in patients at elevated risk

  • Monitor hepatic profile

Requires Special Authorization for PEI Pharmacare

Antimicrobial class: Triazole antifungal, Second generation

Pregnancy category: D

Urine penetration: Poor

Lung penetration: Therapeutic

CSF penetration: Therapeutic